On the 28th, LG Chem announced that its global Phase III clinical trial protocol (EURELIA 2 Study) for ‘tigulixostat’ was approved by the Ministry of Food and Drug Safety. Tigulixostat is a new gout drug candidate being developed by LG Chem.

The Phase III trial will enroll 2,600 gout patients with hyperuricemia around the globe.

LG Chem plans to evaluate the efficacy and safety of tigulixostat in comparison with the existing ‘allopurinol,’ which is commonly used in gout patients, by administering the two drugs for 12 months.

LG Chem explained that it plans to conduct the global clinical trial by submitting the global Phase III protocol for approval in other countries